

Reference number(s)

1169-C

# Initial Prior Authorization with Quantity Limit Kerydin

## **Products Referenced by this Document**

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name	Dosage Form
Kerydin	tavaborole	topical solution

#### **Indications**

### FDA-approved Indications

Kerydin (tavaborole) topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

## **Coverage Criteria**

## Onychomycosis of the Toenail(s)

Authorization may be granted when the requested drug is being prescribed for onychomycosis of the toenail(s) due to Trichophyton rubrum or Trichophyton mentagrophytes when ALL of the following criteria are met:

• The patient's diagnosis has been confirmed with a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy).

Kerydin PA with Limit 1169-C 10-2024\_R.docx

© 2025 CVS Caremark. All rights reserved.

- The patient meets ONE of the following:
  - The patient has experienced an inadequate treatment response to an oral antifungal therapy (e.g., terbinafine, itraconazole).
  - The patient has experienced an intolerance to an oral antifungal therapy (e.g., terbinafine, itraconazole).
  - The patient has a contraindication that would prohibit a trial of an oral antifungal therapy (e.g., terbinafine, itraconazole).
- The requested drug is NOT being used in a footbath.
- If additional quantities are required, multiple toenails are being treated.

# **Quantity Limits Apply**

Treatment of a single nail: 4 mL per 21 days or 12 mL per 63 days

Treatment of multiple nails: 20 mL per 21 days or 60 mL per 63 days

The duration of 21 days is used for a 28-day fill period and 63 days is used for an 84-day fill period to allow time for refill processing.

# **Duration of Approval (DOA)**

• 1169-C: DOA: 12 months

## References

- 1. Kerydin [package insert]. Melville, NY: Fougera Pharmaceuticals Inc.; August 2018.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed September 10, 2024.
- 3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 09/10/2024).
- 4. Frazier WT, Santiago-Delgado ZM, Stupka KC. Onychomycosis: Rapid Evidence Review. American Academy of Family Physicians. 2021;104:359-368.
- 5. Centers for Disease Control (CDC) and Prevention. Treatment of Ringworm and Fungal Nail infections. Available at: https://www.cdc.gov/ringworm/treatment/index.html. Accessed September 10, 2024.

## **Document History**

Written by: UM Development (PL/WW)

Kerydin PA with Limit 1169-C 10-2024\_R.docx

© 2025 CVS Caremark. All rights reserved.

Date Written: 07/2014

Revised: (MS) 05/2015; (KM) 05/2016; (JH) 04/2017 (no clinical changes); (KC) (04/2018); (ME) 02/2019 (no clinical changes); (NZ) 02/2020 (no clinical changes; removed MDC designation); (KC) 12/2020 (added footbath question, quantity limits); (PM) 09/2021 (no clinical changes); (AK/MRS) 09/2022 (no clinical changes); (DRS) 09/2023 (no clinical changes); (SB/DFW) 09/2024 (no clinical changes)

Reviewed: Medical Affairs (LMS) 07/2014; (KU) 05/2015; (ME) 05/2016; (CHART) 02/27/20, 12/31/20, 09/30/21, 09/22/2022, 09/28/2023, 09/26/2024

External Review: 07/2014, 10/2015, 08/2016, 08/2017, 06/2018, 06/2019, 06/2020, 04/2021, 12/2021, 12/2022, 12/2023, 12/2024

CRITI	ERIA FOR APPROVAL		
1	Is the requested drug being prescribed for onychomycosis of the toenail(s) due to Trichophyton rubrum or Trichophyton mentagrophytes? [If Yes, then go to 2. If No, then no further questions.]	Yes	No
2	Has the patient's diagnosis been confirmed with a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy)? [If Yes, then go to 3. If No, then no further questions.]	Yes	No
3	Has the patient experienced an inadequate treatment response to an oral antifungal therapy (e.g., terbinafine, itraconazole)? [If Yes, then go to 6. If No, then go to 4.]	Yes	No
4	Has the patient experienced an intolerance to an oral antifungal therapy (e.g., terbinafine, itraconazole)? [If Yes, then go to 6. If No, then go to 5.]	Yes	No
5	Does the patient have a contraindication that would prohibit a trial of an oral antifungal therapy (e.g., terbinafine, itraconazole)? [If Yes, then go to 6. If No, then no further questions.]	Yes	No
6	Is the requested drug being used in a footbath? [If Yes, then no further questions. If No, then go to 7.]	Yes	No
7	Does the patient require MORE than the plan allowance of 4 mL per month? [NOTE: If higher quantities are needed, additional questions are required.] [If Yes, then go to 8. If No, then no further questions.]	Yes	No

Kerydin PA with Limit 1169-C 10-2024\_R.docx

© 2025 CVS Caremark. All rights reserved.

Reference number(s)
1169-C

Are multiple toenails being treated?

[If Yes, then go to 9. If No, then no further questions.]

RPh Note: If no, then deny and enter a partial approval for 4 mL / 21 days or 12 mL / 63 days.

9 Does the patient require MORE than the plan allowance of 20 mL per month?

Yes No [No further questions]

RPh Note: If yes, then deny and enter a partial approval for 20 mL / 21 days or 60 mL / 63 days.

			Mapping Instructions
	Yes	No	DENIAL REASONS
1.	Go to 2	Deny	Your plan only covers this drug when it is used for certain health conditions. Covered use is for a specific fungal infection of your toenail(s). Your plan does not cover this drug for your health condition that your doctor told us you have. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.  [Short Description: Diagnosis]
2.	Go to 3	Deny	Your plan only covers this drug when you have a fungal diagnostic test. We denied your request because we did not receive your results, or your test result did not show a positive test result. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.  [Short Description: Lab/test]

Kerydin PA with Limit 1169-C 10-2024\_R.docx

© 2025 CVS Caremark. All rights reserved.

3.	Go to 6	Go to 4	
4.	Go to 6	Go to 5	
5.	Go to 6	Deny	Your plan only covers this drug if you have tried an oral antifungal therapy (e.g., terbinafine, itraconazole), and it did not work well for you. We have denied your request because: A) You have not tried it, or B) You do not have a medical reason not to take it. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.  [Short Description: Step therapy]
6.	Deny	Go to 7	Your plan only covers this drug if it is not being used in a footbath. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.  [Short Description: Footbath Use]
7.	Go to 8	[Approve for 12 months. Approve 4 mL/21 days or 12 mL/63 days]. Approve, 12 Months	
8.	Go to 9	Deny	We have denied your request because it is for more than the amount your plan covers (quantity limit). Your plan only covers more of this drug (additional quantities) when you meet the criteria for additional quantities. We reviewed the information we had. We have partially approved your request for this drug up to the amount

Kerydin PA with Limit 1169-C 10-2024\_R.docx

© 2025 CVS Caremark. All rights reserved.

Reference number(s) 1169-C

			your plan covers (4 mL per month). Your request for more drug has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.  [Short Description: Quantity, Post limit criteria not met, Partial denial]
9.	Deny	[Approve for 12 months. Approve 20 mL/21 days or 60 mL/63 days]. Approve, 12 Months	We have denied your request because it is for more than the amount your plan covers (quantity limit). We reviewed the information we had. We have partially approved your request for this drug up to the amount your plan covers (20 mL per month). Your request for more drug has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.  [Short Description: Quantity, Exceeds max limit, Partial denial]